ImmunoChem Therapeutics
ImmunoChem Therapeutics, a Phase 2 clinical-stage Northwestern University spin-out, is developing two clinical assets targeting abnormal neuroinflammation, a major contributor to cognitive decline in Alzheimer’s disease and other dementias, as well as in brain injury and stroke. Its strategy is to conduct a Phase 2 trial in an orphan CNS disease as the fastest path to market and then expand into other neurodegenerative diseases, with Alzheimer’s disease being their ultimate goal.
Contact Name:
Victor Shifrin
Contact Email:
City, State – Congressional District:
Auburndale,
MA
–
4
Technology:
Drug
Funding:
Neurological Disorders and Stroke (NINDS)
NIH Projects:
NIH RePorter for
ImmunoChem Therapeutics
Sponsored Event(s):
